高剂量缓释文拉法辛对重度抑郁症患者的心血管影响。
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.
作者信息
Mbaya Patrick, Alam Faouzi, Ashim Sindhu, Bennett David
机构信息
Department of Psychiatry, Laureate House, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK.
出版信息
Hum Psychopharmacol. 2007 Apr;22(3):129-33. doi: 10.1002/hup.834.
OBJECTIVE
To assess cardiovascular safety profile of high dose Venlafaxine XL in patients with major depression.
METHOD
Effects of high dose venlafaxine (mean 346.15 mg;) on the cardiovascular system in 37 patients with major depressive disorder were evaluated: BP, ECG (PR, QT, QRSD and QTc intervals) and heart rate.
RESULTS
12.5% of patients developed hypertension after starting treatment with venlafaxine. There was an association between heart rate and the dose of venlafaxine although not statistically significant. There was no association between dose of venlafaxine and PR, QT, QRSD and QTc intervals. One patient on 300 mg who was hypertensive and on other medications that may prolong QTc, had mildly prolonged QTc. However this was not clinically significant.
CONCLUSION
This study of subjects on high dose venlafaxine (mean 346.15 mg; range 225-525 mg) did not demonstrate any clinical or statistically significant effects on electrocardiogram (ECG) parameters including PR, QT, QRSD and QTc interval.
目的
评估高剂量缓释文拉法辛在重度抑郁症患者中的心血管安全性。
方法
评估了37例重度抑郁症患者服用高剂量文拉法辛（平均346.15毫克）对心血管系统的影响：血压、心电图（PR、QT、QRSD和QTc间期）及心率。
结果
12.5%的患者在开始服用文拉法辛治疗后出现高血压。心率与文拉法辛剂量之间存在关联，尽管无统计学意义。文拉法辛剂量与PR、QT、QRSD和QTc间期之间无关联。一名服用300毫克且患有高血压并正在服用其他可能延长QTc药物的患者，QTc轻度延长。然而，这在临床上并无显著意义。
结论
这项针对高剂量文拉法辛（平均346.15毫克；范围225 - 525毫克）受试者的研究未显示对包括PR、QT、QRSD和QTc间期在内的心电图参数有任何临床或统计学显著影响。
Zotero 插件